- TRACON Pharmaceuticals ( NASDAQ: TCON ) announced entry into an up to $30M non-recourse financing agreement.
- $3.5M will be funded before December 31, 2022. The additional $26.5M, or a lesser amount based on the amount awarded, will be available subject to the award exceeding a threshold and satisfaction of other conditions set forth in the agreement, with 25% of the total being available to be funded after award announcement and the remainder available over a multi-year period.
For further details see:
TRACON Pharmaceuticals announced $30M attributed to award decision expected in Q1 2023